Nana‐Hawwa Abdul‐Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nana‐Hawwa Abdul‐Rahman has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Carl H. Snyderman
Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
5 shared publications - Sonal Choudhary
Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
4 shared publications - Gerardo Guilarte
Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
3 shared publications Connor Gill
2 shared publications- Lucie Joerg
Albany Medical College Albany New York USA
2 shared publications - Miriam Motlak
Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (10) , e71071
Nutrition as an Overlooked Component of Hidradenitis Suppurativa Management: A Focus on Brewer's Yeast Exclusion
- 8 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (10) , e71071
Open AccessNutrition as an Overlooked Component of Hidradenitis Suppurativa Management: A Focus on Brewer's Yeast Exclusion
- Open Access
- 7 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71184
Omega Fatty Acids in Hair Loss Disorders: A Scoping Review of Preclinical and Clinical Evidence
Background: Omega fatty acids, including polyunsaturated omega‐3 and omega‐6 fatty acids (PUFAs) and monounsaturated omega‐9 fatty acids, regulate inflammation, cellular signaling, and tissue homeostasis, and may influence hair follicle biology and hair growth. The widespread use of dietary supplements for hair loss has been fueled by increasing consumer interest and the rapid spread of health information on social media. Aims: This scoping review synthesizes preclinical and clinical evidence on the role of omega fatty acids in the management of alopecia. Methods: PubMed, Embase, ClinicalTrials.gov , the Cochrane Library, and Ovid MEDLINE were searched from database inception through February 2, 2026. The review was conducted in accordance with the PRISMA‐ScR. Eligible studies were peer‐reviewed, English‐language studies evaluating the relationship between omega fatty acids and hair growth, hair loss, or hair follicle biology in scarring or nonscarring alopecia. Results: Preclinical studies suggest that omega fatty acids may promote dermal papilla cell proliferation, activate signaling pathways involved in hair follicle growth, suppress mediators of androgen‐driven hair loss, and may protect against chemotherapy‐induced follicular apoptosis. Clinical studies have reported improvements in hair density, hair growth, and reduced shedding, although many studies evaluated combination nutritional supplements rather than omega fatty acids alone. In contrast, one clinical study of men with androgenetic alopecia found that higher omega‐3 intake was associated with a lower likelihood of clinical improvement. Limited clinical evidence also suggests that omega fatty acid supplementation may support hair regrowth in alopecia areata through immunomodulatory and anti‐inflammatory effects. Conclusion: Current data do not support omega fatty acid supplementation as a standalone treatment for any alopecia subtype.
- 7 September 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71184
Open AccessOmega Fatty Acids in Hair Loss Disorders: A Scoping Review of Preclinical and Clinical Evidence
Background: Omega fatty acids, including polyunsaturated omega‐3 and omega‐6 fatty acids (PUFAs) and monounsaturated omega‐9 fatty acids, regulate inflammation, cellular signaling, and tissue homeostasis, and may influence hair follicle biology and hair growth. The widespread use of dietary supplements for hair loss has been fueled by increasing consumer interest and the rapid spread of health information on social media. Aims: This scoping review synthesizes preclinical and clinical evidence on the role of omega fatty acids in the management of alopecia. Methods: PubMed, Embase, ClinicalTrials.gov , the Cochrane Library, and Ovid MEDLINE were searched from database inception through February 2, 2026. The review was conducted in accordance with the PRISMA‐ScR. Eligible studies were peer‐reviewed, English‐language studies evaluating the relationship between omega fatty acids and hair growth, hair loss, or hair follicle biology in scarring or nonscarring alopecia. Results: Preclinical studies suggest that omega fatty acids may promote dermal papilla cell proliferation, activate signaling pathways involved in hair follicle growth, suppress mediators of androgen‐driven hair loss, and may protect against chemotherapy‐induced follicular apoptosis. Clinical studies have reported improvements in hair density, hair growth, and reduced shedding, although many studies evaluated combination nutritional supplements rather than omega fatty acids alone. In contrast, one clinical study of men with androgenetic alopecia found that higher omega‐3 intake was associated with a lower likelihood of clinical improvement. Limited clinical evidence also suggests that omega fatty acid supplementation may support hair regrowth in alopecia areata through immunomodulatory and anti‐inflammatory effects. Conclusion: Current data do not support omega fatty acid supplementation as a standalone treatment for any alopecia subtype.
- 7 September 2026
- Published by Elsevier in Acta Astronautica
- Vol. 250, 163-174
Cutaneous changes associated with spaceflight and spaceflight analogs: A scoping review
- 7 September 2026
- Published by Elsevier in Acta Astronautica
- Vol. 250, 163-174
Cutaneous changes associated with spaceflight and spaceflight analogs: A scoping review
- Open Access
- 17 August 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Hospitalization Utilization Metric After Major Oncologic Head and Neck Surgery With Microvascular Free Flap
Objective: The primary length of stay (PLOS) metric fails to capture added time, costs, and reduced patient quality of life (QOL) associated with readmissions. To address these limitations, we propose a novel metric, the hospitalization utilization metric (HUM), which integrates PLOS and readmission LOS (RLOS). Study Design: Retrospective review of 626 head and neck microvascular free flap (MVFF) cases from August 2019 to May 2024. Setting: University of Pittsburgh Medical Center. Methods: Main outcome measure was HUM, calculated as total length of stay (TLOS) (TLOS = [PLOS + RLOS]/60 days). High HUM, determined by median split, was >0.18. Results: Our 626‐patient cohort averaged 62.7 ± 11.9 years old. The majority of patients were male (68.2%), white (92.0%), with advanced tumors (III/IV: 74.1%), and public insurance (63.1%). The median (interquartile range [IQR]) PLOS was 9 (7‐14), median (IQR) HUM was 0.18 (0.13‐0.28), and the rate of 60‐day re‐presentation/readmission was 34.3%. Multivariable logistic regression identified postoperative complications ( β : .08, P < .001; β : 4.44, P < .001, respectively) and private insurance ( β : −.04, P < .02; −2.71, P < .01) as predictive factors associated with both higher HUM and PLOS (>9 days), respectively. Return to intensive care unit (ICU) ( β : .08, P < .003) and duration of surgery ( β : .005, P < .048) were independently associated with higher HUM, although both effect sizes are relatively small. Kaplan‐Meier survival curves revealed that higher HUM ( P = .030) but not PLOS ( P = .098) was associated with worse survival 1 year postoperatively. Conclusion: HUM provides a comprehensive assessment of healthcare utilization compared to PLOS and re‐presentation alone and may be a practical surrogate for patient QOL and healthcare costs.
- 17 August 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Open AccessHospitalization Utilization Metric After Major Oncologic Head and Neck Surgery With Microvascular Free Flap
Objective: The primary length of stay (PLOS) metric fails to capture added time, costs, and reduced patient quality of life (QOL) associated with readmissions. To address these limitations, we propose a novel metric, the hospitalization utilization metric (HUM), which integrates PLOS and readmission LOS (RLOS). Study Design: Retrospective review of 626 head and neck microvascular free flap (MVFF) cases from August 2019 to May 2024. Setting: University of Pittsburgh Medical Center. Methods: Main outcome measure was HUM, calculated as total length of stay (TLOS) (TLOS = [PLOS + RLOS]/60 days). High HUM, determined by median split, was >0.18. Results: Our 626‐patient cohort averaged 62.7 ± 11.9 years old. The majority of patients were male (68.2%), white (92.0%), with advanced tumors (III/IV: 74.1%), and public insurance (63.1%). The median (interquartile range [IQR]) PLOS was 9 (7‐14), median (IQR) HUM was 0.18 (0.13‐0.28), and the rate of 60‐day re‐presentation/readmission was 34.3%. Multivariable logistic regression identified postoperative complications ( β : .08, P < .001; β : 4.44, P < .001, respectively) and private insurance ( β : −.04, P < .02; −2.71, P < .01) as predictive factors associated with both higher HUM and PLOS (>9 days), respectively. Return to intensive care unit (ICU) ( β : .08, P < .003) and duration of surgery ( β : .005, P < .048) were independently associated with higher HUM, although both effect sizes are relatively small. Kaplan‐Meier survival curves revealed that higher HUM ( P = .030) but not PLOS ( P = .098) was associated with worse survival 1 year postoperatively. Conclusion: HUM provides a comprehensive assessment of healthcare utilization compared to PLOS and re‐presentation alone and may be a practical surrogate for patient QOL and healthcare costs.
- Open Access
- 6 February 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (7) , 2963-2970
Factors Affecting Outcomes in Anterior Cervical Spine Surgery
Objective: To evaluate procedure‐related complications after ACSS and identify key influential factors that increase or decrease the risk of perioperative complications. Methods: This single institution retrospective cohort study included 3401 patients who underwent ACSS by spine‐surgeons at a single institution from January 2015 to August 2023. Our main outcome of interest was perioperative complications after ACSS, divided into objective and subjective outcomes. Covariates included patient, procedure, surgeon, and institutional factors. Univariable and multivariable logistic regression were used to identify factors associated with complications. Results: Our cohort included 3401 patients averaging 55 ± 12 years and 50% ( n = 1689) were male. The objective complication rate was 4.44% ( n = 151) and subjective complications were 6.70% ( n = 228). Otolaryngologists were involved in 17% ( n = 591) of cases. On multivariable logistic regression, high volume (≥ 15 annual cases) surgeons (OR: 0.58, 95% Cl: 0.35–0.95, p = 0.030), and otolaryngologist involvement in revision surgeries (OR: 0.31, 95% Cl: 0.12–0.77, p = 0.011) were independent predictors of decreased odds of objective complications. Advanced age (OR: 1.04, 95% Cl: 1.02–1.05, p < 0.001) and surgeries involving multiple (≥ 3) spinal levels (OR: 1.70, 95% Cl: 1.23–2.34, p = 0.001) independently predicted an increased odd of subjective complications. Otolaryngologist involvement in upper (C1–4) cervical spinal cases (OR: 0.28, 95% Cl: 0.08–0.96, p = 0.042) independently decreased odds of subjective complications. Conclusion: Adopting a multidisciplinary approach with otolaryngologists as co‐surgeons in complex procedures and increasing surgeons' case volume may improve surgical outcomes, decrease complication rates, and improve quality of care. Level of Evidence: 4
- 6 February 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (7) , 2963-2970
Open AccessFactors Affecting Outcomes in Anterior Cervical Spine Surgery
Objective: To evaluate procedure‐related complications after ACSS and identify key influential factors that increase or decrease the risk of perioperative complications. Methods: This single institution retrospective cohort study included 3401 patients who underwent ACSS by spine‐surgeons at a single institution from January 2015 to August 2023. Our main outcome of interest was perioperative complications after ACSS, divided into objective and subjective outcomes. Covariates included patient, procedure, surgeon, and institutional factors. Univariable and multivariable logistic regression were used to identify factors associated with complications. Results: Our cohort included 3401 patients averaging 55 ± 12 years and 50% ( n = 1689) were male. The objective complication rate was 4.44% ( n = 151) and subjective complications were 6.70% ( n = 228). Otolaryngologists were involved in 17% ( n = 591) of cases. On multivariable logistic regression, high volume (≥ 15 annual cases) surgeons (OR: 0.58, 95% Cl: 0.35–0.95, p = 0.030), and otolaryngologist involvement in revision surgeries (OR: 0.31, 95% Cl: 0.12–0.77, p = 0.011) were independent predictors of decreased odds of objective complications. Advanced age (OR: 1.04, 95% Cl: 1.02–1.05, p < 0.001) and surgeries involving multiple (≥ 3) spinal levels (OR: 1.70, 95% Cl: 1.23–2.34, p = 0.001) independently predicted an increased odd of subjective complications. Otolaryngologist involvement in upper (C1–4) cervical spinal cases (OR: 0.28, 95% Cl: 0.08–0.96, p = 0.042) independently decreased odds of subjective complications. Conclusion: Adopting a multidisciplinary approach with otolaryngologists as co‐surgeons in complex procedures and increasing surgeons' case volume may improve surgical outcomes, decrease complication rates, and improve quality of care. Level of Evidence: 4
- Open Access
- 16 January 2026
- Published by Wiley in Head & Neck
- Vol. 48 (6) , 1567-1578
Transoral Styloidectomy Approach: A Systematic Review and Enhanced Endoscopic Approach
Background: Synthesize transoral styloidectomy approaches, highlight advantages, disadvantages, surgical outcomes, and describe an improved endoscopic transoral technique. Methods: A systematic review of peer‐reviewed articles was conducted on November 11, 2025 in PubMed, Embase, the Cochrane Library, and Medline. Results: Of the 204 articles screened, 45 met inclusion criteria. Four transoral approaches and four visual enhancement techniques were described. Surgical success rate was 94% with no intraoperative complications and a postoperative complication rate of 6.3%. The length of resected styloid averaged 2.91 ± 1.33 cm (range: 1–6 cm). Mean operative time was 47 ± 22 min. Median follow‐up time was 6 months (IQR: 3–12 months). Conclusion: Transoral styloidectomy is safe and effective for the treatment of Eagle's syndrome. An enhanced endoscopic approach with indocyanine green (ICG) fluoroscopy and neuromonitoring improves intraoperative visualization and helps identify critical vascular structures, potentially reducing the risk of inadvertent injury.
- 16 January 2026
- Published by Wiley in Head & Neck
- Vol. 48 (6) , 1567-1578
Open AccessTransoral Styloidectomy Approach: A Systematic Review and Enhanced Endoscopic Approach
Background: Synthesize transoral styloidectomy approaches, highlight advantages, disadvantages, surgical outcomes, and describe an improved endoscopic transoral technique. Methods: A systematic review of peer‐reviewed articles was conducted on November 11, 2025 in PubMed, Embase, the Cochrane Library, and Medline. Results: Of the 204 articles screened, 45 met inclusion criteria. Four transoral approaches and four visual enhancement techniques were described. Surgical success rate was 94% with no intraoperative complications and a postoperative complication rate of 6.3%. The length of resected styloid averaged 2.91 ± 1.33 cm (range: 1–6 cm). Mean operative time was 47 ± 22 min. Median follow‐up time was 6 months (IQR: 3–12 months). Conclusion: Transoral styloidectomy is safe and effective for the treatment of Eagle's syndrome. An enhanced endoscopic approach with indocyanine green (ICG) fluoroscopy and neuromonitoring improves intraoperative visualization and helps identify critical vascular structures, potentially reducing the risk of inadvertent injury.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 7236883
L‐Histidine as a Biologic Modulator and Therapeutic Target for Atopic Dermatitis: A Narrative Review of Mechanisms, Evidence, and Clinical Implications
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and intense pruritus. Although existing treatments, including topical corticosteroids, calcineurin inhibitors, and biologic agents, are effective for many patients, concerns regarding long‐term safety, cost, and incomplete disease control have driven interest in nonimmunosuppressive and complementary therapeutic strategies. L‐histidine is an essential dietary amino acid that has emerged as a potential biologic modulator in AD due to its central role in filaggrin metabolism and natural moisturizing factor (NMF) production. This narrative review synthesizes the current mechanistic, preclinical, and clinical evidence evaluating L‐histidine as a therapeutic or adjunctive intervention in AD. L‐histidine supports epidermal hydration, pH homeostasis, and barrier integrity through its role as a precursor of filaggrin‐derived NMF components. In vitro and skin‐equivalent models demonstrate that L‐histidine enhances filaggrin processing and improves functional barrier properties. Importantly, mechanistic studies indicate that histidine supplementation does not promote pathological histamine production, alleviating concerns regarding histamine‐mediated disease exacerbation. Clinical evidence, though limited to small exploratory trials and case reports, shows reductions in disease severity and pruritus in both pediatric and adult patients receiving oral L‐histidine supplementation. However, these findings should be regarded as preliminary rather than conclusive. The magnitude of improvement reported in these small trials has been described by the authors as similar to SCORAD reductions historically reported for mid‐potency topical corticosteroids. However, this is a benchmark comparison against external historical literature, not a head‐to‐head assessment. Since no head‐to‐head trial has directly compared L‐histidine with topical corticosteroids, its efficacy should not be considered equivalent or directly comparable to that of topical corticosteroids. Oral L‐histidine has demonstrated a favorable safety and tolerability profile to date, with no serious adverse events reported. L‐histidine is a low‐cost, well‐tolerated, barrier‐targeted adjunct with potential utility in AD management. Larger, long‐term randomized controlled trials incorporating genetic stratification and combination therapy designs are warranted to better define its optimal role in clinical practice.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 7236883
Open AccessL‐Histidine as a Biologic Modulator and Therapeutic Target for Atopic Dermatitis: A Narrative Review of Mechanisms, Evidence, and Clinical Implications
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and intense pruritus. Although existing treatments, including topical corticosteroids, calcineurin inhibitors, and biologic agents, are effective for many patients, concerns regarding long‐term safety, cost, and incomplete disease control have driven interest in nonimmunosuppressive and complementary therapeutic strategies. L‐histidine is an essential dietary amino acid that has emerged as a potential biologic modulator in AD due to its central role in filaggrin metabolism and natural moisturizing factor (NMF) production. This narrative review synthesizes the current mechanistic, preclinical, and clinical evidence evaluating L‐histidine as a therapeutic or adjunctive intervention in AD. L‐histidine supports epidermal hydration, pH homeostasis, and barrier integrity through its role as a precursor of filaggrin‐derived NMF components. In vitro and skin‐equivalent models demonstrate that L‐histidine enhances filaggrin processing and improves functional barrier properties. Importantly, mechanistic studies indicate that histidine supplementation does not promote pathological histamine production, alleviating concerns regarding histamine‐mediated disease exacerbation. Clinical evidence, though limited to small exploratory trials and case reports, shows reductions in disease severity and pruritus in both pediatric and adult patients receiving oral L‐histidine supplementation. However, these findings should be regarded as preliminary rather than conclusive. The magnitude of improvement reported in these small trials has been described by the authors as similar to SCORAD reductions historically reported for mid‐potency topical corticosteroids. However, this is a benchmark comparison against external historical literature, not a head‐to‐head assessment. Since no head‐to‐head trial has directly compared L‐histidine with topical corticosteroids, its efficacy should not be considered equivalent or directly comparable to that of topical corticosteroids. Oral L‐histidine has demonstrated a favorable safety and tolerability profile to date, with no serious adverse events reported. L‐histidine is a low‐cost, well‐tolerated, barrier‐targeted adjunct with potential utility in AD management. Larger, long‐term randomized controlled trials incorporating genetic stratification and combination therapy designs are warranted to better define its optimal role in clinical practice.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
The Use of Methylsulfonylmethane‐Containing Products in Dermatology: An Evidence‐Based Systematic Review of Safety and Efficacy
Background: Methylsulfonylmethane (MSM) is a biologically active sulfur compound that has been implicated in structural protein synthesis and anti‐inflammatory signaling pathways. We conducted a systematic review to evaluate the efficacy and safety of MSM in skin care products and explore the underlying mechanism of action. Methods: This review followed PRISMA guidelines and was registered on PROSPERO (CRD420251274679). PubMed, Embase, ClinicalTrials.gov, Cochrane Library, and Ovid/MEDLINE were searched from inception through December 23, 2025. Eligible studies evaluated topical or oral MSM for dermatologic conditions in human participants. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool for randomized control trials and the Newcastle–Ottawa Scale for nonrandomized studies. Results: Of the 228 records identified, seven studies ( n = 416) met the inclusion criteria: six randomized controlled trials and one case report, in adults with acne vulgaris, erythematous‐telangiectatic rosacea, nail psoriasis, skin aging, and X‐linked ichthyosis. MSM‐containing interventions (both topical and oral) were associated with statistically significant improvements in clinical severity and skin‐related outcomes, including inflammatory lesion counts, erythema, nail severity scores, and measures of skin hydration, elasticity, firmness, texture, and dermal thickness. Reported adverse events were mild and transient, with no serious adverse events or treatment‐related withdrawals. Conclusions: The most reliable evidence supports oral MSM for photoaging, moderate support for acne, erythematous‐telangiectatic rosacea, and nail psoriasis, and weakest evidence for X‐linked ichthyosis. Importantly, studies lasting up to 24 weeks did not identify any serious safety concerns.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessThe Use of Methylsulfonylmethane‐Containing Products in Dermatology: An Evidence‐Based Systematic Review of Safety and Efficacy
Background: Methylsulfonylmethane (MSM) is a biologically active sulfur compound that has been implicated in structural protein synthesis and anti‐inflammatory signaling pathways. We conducted a systematic review to evaluate the efficacy and safety of MSM in skin care products and explore the underlying mechanism of action. Methods: This review followed PRISMA guidelines and was registered on PROSPERO (CRD420251274679). PubMed, Embase, ClinicalTrials.gov, Cochrane Library, and Ovid/MEDLINE were searched from inception through December 23, 2025. Eligible studies evaluated topical or oral MSM for dermatologic conditions in human participants. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool for randomized control trials and the Newcastle–Ottawa Scale for nonrandomized studies. Results: Of the 228 records identified, seven studies ( n = 416) met the inclusion criteria: six randomized controlled trials and one case report, in adults with acne vulgaris, erythematous‐telangiectatic rosacea, nail psoriasis, skin aging, and X‐linked ichthyosis. MSM‐containing interventions (both topical and oral) were associated with statistically significant improvements in clinical severity and skin‐related outcomes, including inflammatory lesion counts, erythema, nail severity scores, and measures of skin hydration, elasticity, firmness, texture, and dermal thickness. Reported adverse events were mild and transient, with no serious adverse events or treatment‐related withdrawals. Conclusions: The most reliable evidence supports oral MSM for photoaging, moderate support for acne, erythematous‐telangiectatic rosacea, and nail psoriasis, and weakest evidence for X‐linked ichthyosis. Importantly, studies lasting up to 24 weeks did not identify any serious safety concerns.
- 23 May 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 173 (3) , 603-612
Incidence, Morbidity, and Mortality of Pulmonary Complications in Free Flap Reconstruction: Limitations of Predictive Models
Objective: Herein, we evaluate the incidence, risk factors, and prognostic implications of postoperative pulmonary complications (PPCs) in head and neck microvascular free flap (MVFF) reconstruction. Current prediction models were assessed, and a head and neck MVFF‐specific model is proposed.Study Design: Retrospective review of 638 head and neck MVFF cases from August 2019 to May 2024.Setting: Tertiary academic center.Methods: Data were collected via chart review focusing on preoperative, intraoperative, and postoperative risk factors for PPCs within 30 days of surgery.Results: Grades 2 to 5 PPCs occurred in 27% of patients. Predictors of PPCs in univariate analysis include prolonged surgery (mean: 10.06 ± 2.67 hours, P = .006), estimated blood loss ≥ 200 mL (n = 111, P = .006), advanced tumor stage (III/IV: n = 123, P = .013), hematoma (n = 25, P < .001), and postoperative transfusion (n = 20, P = .037). Tumor stage (odds ratio [OR] 1.29, 95% CI 1.06‐1.57, P = .012), surgery duration (OR 1.08, 95% CI 1.01‐1.17, P = .031), and hematoma (OR 2.98, 95% CI 1.50‐5.94, P = .002) remained significant predictors of grades 2 to 5 PPCs on multivariable analysis. In‐hospital mortality was 1.4% (n = 9), and all experienced grade 5 PPCs. The 1‐year mortality rate was 13.48 per 100 patients, with significantly lower survival in patients with grades 2 to 5 PPCs (75.6% vs 89.4%). PPC was independently associated with mortality (hazard ratio [HR] 3.94, 95% CI 1.69‐9.22, P = .002). Our model (area under the curve [AUC] 0.65) outperformed the ARISCAT (AUC = 0.51) and Gupta scores (AUC = 0.45) in predicting PPCs.Conclusion: PPCs are common after MVFF, contributing to significant morbidity and mortality. Current models are inadequate, highlighting the need for a tailored model specific to oncologic head and neck surgery.
- 23 May 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 173 (3) , 603-612
Incidence, Morbidity, and Mortality of Pulmonary Complications in Free Flap Reconstruction: Limitations of Predictive Models
Objective: Herein, we evaluate the incidence, risk factors, and prognostic implications of postoperative pulmonary complications (PPCs) in head and neck microvascular free flap (MVFF) reconstruction. Current prediction models were assessed, and a head and neck MVFF‐specific model is proposed.Study Design: Retrospective review of 638 head and neck MVFF cases from August 2019 to May 2024.Setting: Tertiary academic center.Methods: Data were collected via chart review focusing on preoperative, intraoperative, and postoperative risk factors for PPCs within 30 days of surgery.Results: Grades 2 to 5 PPCs occurred in 27% of patients. Predictors of PPCs in univariate analysis include prolonged surgery (mean: 10.06 ± 2.67 hours, P = .006), estimated blood loss ≥ 200 mL (n = 111, P = .006), advanced tumor stage (III/IV: n = 123, P = .013), hematoma (n = 25, P < .001), and postoperative transfusion (n = 20, P = .037). Tumor stage (odds ratio [OR] 1.29, 95% CI 1.06‐1.57, P = .012), surgery duration (OR 1.08, 95% CI 1.01‐1.17, P = .031), and hematoma (OR 2.98, 95% CI 1.50‐5.94, P = .002) remained significant predictors of grades 2 to 5 PPCs on multivariable analysis. In‐hospital mortality was 1.4% (n = 9), and all experienced grade 5 PPCs. The 1‐year mortality rate was 13.48 per 100 patients, with significantly lower survival in patients with grades 2 to 5 PPCs (75.6% vs 89.4%). PPC was independently associated with mortality (hazard ratio [HR] 3.94, 95% CI 1.69‐9.22, P = .002). Our model (area under the curve [AUC] 0.65) outperformed the ARISCAT (AUC = 0.51) and Gupta scores (AUC = 0.45) in predicting PPCs.Conclusion: PPCs are common after MVFF, contributing to significant morbidity and mortality. Current models are inadequate, highlighting the need for a tailored model specific to oncologic head and neck surgery.